Contact information
Biography
I studied Medicine at the University of Birmingham (1991-97) and continued my general medical training in Oxford. I then spent three years working on the genetic linkage and association of neurological disorders at the Wellcome Trust Centre for Human Genetics. After obtaining my DPhil in 2003, I completed my training in Clinical Neurology at Oxford. I joined the Department of Physiology, Anatomy and Genetics in 2007 after being awarded an MRC Clinician Scientist Fellowship to establish my own research group. I then led IMI StemBANCC - an large public-private partnerhsip funded by the EU to establish iPSC resources for academia and industry across europe.
I now lead IMI IM2PACT which is an amibitious research programme to investigate disease mechanism involving the brain neurovascular unit and find transport mechanisms to get therapeutics into the brain.
My research group aims to develop resources and tools to improve drug discovery by leveraging human data and human iPSC brain models. We work on pain/migraine, Alzheimer's disease and autism/epilepsy.
I am also active clinically and work as a Consultant Neurologist at the John Radcliffe Hospital with an interest in Headache Disorders. I am Director of the Oxford Headache Centre and developed the Oxford Community Headache Service.
Zameel Cader
DPhil, MRCP
Director of the Oxford Headache Centre and Director of StemBANCC
- Professor of Neuroscience and Neurology
- Consultant Neurologist
Molecular disease mechanisms and cellular disease phenotypes in neurological disorders
Research groups
Websites
-
Kavli Institute for Nanoscience Discovery
Research centre
-
IM2PACT
Investigating Transport Mechanism and Disease Targets of the Blood-Brain-Barrier
-
stemBANCC
stem cells for drug discovery
-
Oxford Stem Cells
Oxford Stem Cell Institute
Research summary
The Translational Molecular Neuroscience Group looks at neurogenetic disorders, often rare variants of common disease. Understanding the disease pathways in these conditions will allow development of meaningful therapies. The group is developing new disease models for more effective drug discovery platforms.
Sources of Funding
- EU FP7
- Wellcome Trust
- NIHR BRC
- Medical Research Council
- John Fell
Recent publications
-
From Young to Old: Mimicking Neuronal Aging in Directly Converted Neurons from Young Donors
Journal article
Varghese N. et al, (2024), Cells, 13, 1260 - 1260
-
Human iPSCs from aged donors retain their mitochondrial aging signature
Preprint
Lejri I. et al, (2024)
-
Preservation of an Aging-Associated Mitochondrial Signature in Advanced Human Neuronal Models
Preprint
Varghese N. et al, (2024)
-
Aneuploidy effects on human gene expression across three cell types.
Journal article
Liu S. et al, (2023), Proc Natl Acad Sci U S A, 120
-
A novel human iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases in extracellular matrix abnormalities
Preprint
Al-Thani M. et al, (2023)